Arthritis and immune-mediated bone loss - role of estrogen signalling pathways
Sammanfattning
Objective: Rheumatoid arthritis (RA) is associated with immune-mediated bone loss and thereby increased risk for fractures. Estrogen and selective estrogen receptor modulators (SERMs) ameliorate not only the incidence and progression of experimental RA but also the immune-mediated bone loss. The aim of this thesis was to elucidate estrogen signaling pathways in arthritis and the associated immune-mediated bone loss.
Methods: Arthritis and bone mineral density (BMD) were evaluated in two experimental models of arthritis, collagen-induced arthritis (CIA) and antigen-induced arthritis (AIA). Specific estrogen receptor (ER) agonists and transgenic mouse models (total ERα knockout (KO), cartilage-specific ERα KO and ERE-luciferase reporter mice) were used, and the resulting phenotypes were examined by histological evaluation and peripheral quantitative computerized tomography.
Results: The ameliorating effect of estrogen on arthritis and associated bone loss was mediated via ERα, as determined by CIA using a specific ERα agonist and confirmed in total ERα KO mice using AIA. Furthermore, the amelioration of joint destruction was mediated via ERα in non-chondrocytes but for synovitis via ERα in chondrocytes. AIA resulted not only in bone erosions, but also in decreased periarticular BMD and can be used as a model to study periarticular bone loss. The SERM raloxifene exerted its effects by inducing the classical genomic estrogen signaling pathway in bone in vivo.
Conclusions: ERα mediates estrogens ameliorating effect on arthritis and immune-mediated bone loss. Estrogen ameliorates joint destruction and synovitis via ERα by two different mechanisms.
Long-term treatment with estrogen is associated with significant side effects. Thus increased understanding of the mechanisms behind the beneficial effects of estrogen and SERMs is important in the search for novel treatments of arthritis, including postmenopausal RA, and immune-mediated bone loss.
Delarbeten
Paper I; Cecilia Engdahl, Caroline Jochems, Sara H Windahl, Anna E Börjesson, Claes Ohlsson, Hans Carlsten, Marie K Lagerquist. Amelioration of collagen-induced arthritis and immune-associated bone loss through signaling via estrogen receptor alpha, and not estrogen receptor beta or G protein-coupled receptor 30. Arthritis Rheum. 2010 Feb; 62(2):524-33 ::PMID::20112355 Paper II; Cecilia Engdahl, Anna E Börjesson, Annica Andersson, Alexandra Stubelius, Andree Krust, Pierre Chambon, Ulrika Islander, Claes Ohlsson, Hans Carlsten, Marie K Lagerquist. The role of total and cartilage-specific ERα expression for the ameliorating effect of estrogen on arthritis. Manuscript. Paper III;Ceclia Engdahl, Catharina Lindholm, Alexandra Stubelius, Claes Ohlsson, Hans Carlsten, Marie K Lagerquist. Periarticular bone loss in antigen-induced arthritis. Manuscript. Paper IV; Cecilia Engdahl, Caroline Jochems, Jan-Åke Gustafsson, Paul T van der Saag, Hans Carlsten, Marie K Lagerquist. In vivo activation of gene transcription via oestrogen response elements by a raloxifene analogue. Journal of Endocrinology. 2009 Dec; 203(3): 349-56 ::PMID::19752149
Examinationsnivå
Doctor of Philosophy (Medicine)
Universitet
University of Gothenburg. Sahlgrenska Academy
Institution
Institute of Medicine. Department of Rheumatology and Inflammation Research
Disputation
Fredagen den 11 januari 2013, klockan 9.00, Förelässningssalen, tredje våningen, Guldhedsgatan10A, Göteborg
Datum för disputation
2013-01-11
E-post
cecilia.engdahl@gu.se
Datum
2012-12-13Författare
Engdahl, Cecilia
Nyckelord
Arthritis
Bone
Estrogen
Publikationstyp
Doctoral thesis
ISBN
978-91-628-8577-9
Språk
eng